Epidermal Growth Factor clinical trials

Explore recruiting epidermal growth factor clinical trials.

Recruiting epidermal growth factor studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Epidermal Growth Factor trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Randomized, Open-label, Phase 3 Study of MK-2870 vs Chemotherapy (Docetaxel or Pemetrexed) in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) with EGFR Mutations or Other Genomic Alterations

Greece, Poland, Germany, Czechia, France, Italy +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Palbociclib plus fulvestrant in women with hormone receptor positive and human epidermal growth factor receptor type 2 negative locally advanced or metastatic breast cancer previously treated with a CDK4/6 inhibitor in combination with hormonal therapy: a multicenter, phase II trial

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

First in human study of BAY2927088 in participants who have advanced non-small cell lung cancer (NSCLC) with mutations in the genes of epidermal growth factor receptor (EGFR) and/or human epidermal growth factor receptor 2 (HER2)

Netherlands, Spain, Belgium, Italy, Portugal, France +1 more

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

C4251003- A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated, Locally Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations.

Germany, Belgium, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

I3Y-MC-JPCG: A Randomized, Open-Label, Phase 2 Study of Abemaciclib Plus Tamoxifen or Abemaciclib Alone, in Women With Previously Treated Hormone Receptor-Positive, HER2-Negative, Metastatic Breast Cancer

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Boosting osimertinib Blood Brain Barrier penetration in patients with epidermal growth factor receptor mutated non-small cell lung cancer (OSIBBBOOST)

Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

Epidermal Growth Factor trials by city

Epidermal Growth Factor in Toronto Epidermal Growth Factor in Vancouver Epidermal Growth Factor in Montreal Epidermal Growth Factor in Calgary Epidermal Growth Factor in Edmonton Epidermal Growth Factor in Ottawa Epidermal Growth Factor in Winnipeg Epidermal Growth Factor in Quebec City Epidermal Growth Factor in Hamilton Epidermal Growth Factor in Kitchener Epidermal Growth Factor in London Epidermal Growth Factor in Halifax Epidermal Growth Factor in New York Epidermal Growth Factor in Los Angeles Epidermal Growth Factor in Chicago Epidermal Growth Factor in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease